5-fluorouracil + cyclophosphamide + doxorubicin + epirubicin + methotrexate + mitomycin C + paclitaxel

This is a multi-agent chemotherapy combination consisting of seven cytotoxic drugs: 5-fluorouracil, cyclophosphamide, doxorubicin, epirubicin, methotrexate, mitomycin C, and paclitaxel. Each component has a distinct mechanism of action targeting cancer cell proliferation and survival. Such combinations are used in oncology to maximize tumor cell kill by attacking cancer through multiple pathways and reducing the likelihood of drug resistance. These regimens are primarily used for the treatment of various solid tumors (notably breast cancer), though this specific seven-drug combination is not standard; subsets such as FAC (fluorouracil, doxorubicin [Adriamycin], cyclophosphamide) or FEC (fluorouracil, epirubicin, cyclophosphamide) are well-established in clinical practice[1][3][4][5]. The inclusion of all seven agents would be highly intensive and reserved for investigational or salvage settings due to cumulative toxicity.